Kirstein MN - Search Results

1

Exposure-response relationships for oxaliplatin-treated colon cancer cells.

Kirstein MN, Root SA, Moore MM, Wieman KM, Williams BW, Jacobson PA, Marker PH, Tuttle TM. Kirstein MN, et al. Anticancer Drugs. 2008 Jan;19(1):37-44. doi: 10.1097/CAD.0b013e3282f07791. Anticancer Drugs. 2008. PMID: 18043128

2

Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system.

Kirstein MN, Wieman KM, Williams BW, Fisher JE, Marker PH, Le CT, Yee D, Kratzke RA. Kirstein MN, et al. Lung Cancer. 2007 Nov;58(2):196-204. doi: 10.1016/j.lungcan.2007.06.005. Epub 2007 Jul 25. Lung Cancer. 2007. PMID: 17651859

3

Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system.

Kirstein MN, Brundage RC, Moore MM, Williams BW, Hillman LA, Dagit JW, Fisher JE, Marker PH, Kratzke RA, Yee D. Kirstein MN, et al. Cancer Chemother Pharmacol. 2008 Feb;61(2):291-9. doi: 10.1007/s00280-007-0474-z. Epub 2007 Apr 12. Cancer Chemother Pharmacol. 2008. PMID: 17429628

4

Review of selected patents for cancer therapy targeting tumor angiogenesis.

Kirstein MN, Moore MM, Dudek AZ. Kirstein MN, et al. Recent Pat Anticancer Drug Discov. 2006 Jun;1(2):153-61. doi: 10.2174/157489206777442269. Recent Pat Anticancer Drug Discov. 2006. PMID: 18221033 Review.

5

Cap-dependent translation blockade and fixed dose-rate gemcitabine: interaction in an in vitro bioreactor system.

Williams BW, Chang JJ, Chi RM, Marker PH, Frethem CD, Le CT, Kratzke RA, Kirstein MN. Williams BW, et al. Among authors: kirstein mn. Cancer Lett. 2009 Oct 18;284(1):37-46. doi: 10.1016/j.canlet.2009.04.006. Epub 2009 May 12. Cancer Lett. 2009. PMID: 19442436

6

Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C.

Rueth NM, Murray SE, Huddleston SJ, Abbott AM, Greeno EW, Kirstein MN, Tuttle TM. Rueth NM, et al. Among authors: kirstein mn. Ann Surg Oncol. 2011 Jan;18(1):174-80. doi: 10.1245/s10434-010-1210-1. Epub 2010 Jul 8. Ann Surg Oncol. 2011. PMID: 20614192 Clinical Trial.

7

Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine.

Khatri A, Brundage RC, Hull JM, Williams BW, Yee D, Kirstein MN. Khatri A, et al. Among authors: kirstein mn. AAPS J. 2012 Mar;14(1):1-9. doi: 10.1208/s12248-011-9308-3. Epub 2011 Nov 19. AAPS J. 2012. PMID: 22101930 Free PMC article.

8

Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens.

Kirstein MN, Brundage RC, Elmquist WF, Remmel RP, Marker PH, Guire DE, Yee D. Kirstein MN, et al. Breast Cancer Res Treat. 2006 Apr;96(3):217-25. doi: 10.1007/s10549-005-9004-z. Breast Cancer Res Treat. 2006. PMID: 16502018

9

Combinatorial pharmacologic effects of gemcitabine and its metabolite dFdU.

Benyumov A, Gurvich VJ, Lis LG, Williams BW, Kirstein MN. Benyumov A, et al. Among authors: kirstein mn. ChemMedChem. 2011 Mar 7;6(3):457-64. doi: 10.1002/cmdc.201000447. Epub 2011 Jan 30. ChemMedChem. 2011. PMID: 21280228

10

Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.

Liang S, Brundage RC, Jacobson PA, Blaes A, Kirstein MN. Liang S, et al. Among authors: kirstein mn. Br J Clin Pharmacol. 2016 Sep;82(3):773-83. doi: 10.1111/bcp.12989. Epub 2016 Jun 3. Br J Clin Pharmacol. 2016. PMID: 27128712 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters